Ikeda H, Nagashima K, Matsuyama S, Okumura H, Nagamachi Y
1st Dept. of Surgery, Gunma Univ. School of Med.
Gan No Rinsho. 1988 Jul;34(8):953-60.
Ten patients in stages III or IV of neuroblastoma have been receiving treatment on the basis of a group study protocol that is supported by grant from the Ministry of Health and Welfare. Their chemotherapy regimen has consisted of a combination of cyclophosphamide, vincristine, THP-adriamycin, cisplatin, nimustine and dacarbazine. Surgery has been performed on all patients and in 7 patients their primary tumors were resected either as a delayed primary operation or a second look operation. Radiotherapy has been used for four patients at a total dose of 22-40 Gy. Six patients still survive (survival time: 5-27 months) with time spans that have ranged from 2-19 months of complete response. Major complications have been renal insufficiency, hearing loss, cardiac insufficiency, and bone marrow suppression, We focus mainly on the problems of this multidisciplinary treatment protocol.
10例Ⅲ期或Ⅳ期神经母细胞瘤患者一直在按照一项由厚生省资助的分组研究方案接受治疗。他们的化疗方案包括环磷酰胺、长春新碱、吡柔比星、顺铂、尼莫司汀和达卡巴嗪联合使用。所有患者均接受了手术治疗，其中7例患者的原发肿瘤通过延迟一期手术或二次探查手术得以切除。4例患者接受了放疗，总剂量为22 - 40 Gy。6例患者仍然存活（生存时间：5 - 27个月），完全缓解时间跨度为2 - 19个月。主要并发症包括肾功能不全、听力丧失、心功能不全和骨髓抑制。我们主要关注这种多学科治疗方案的问题。
